Lee Jennifer Kayden 4

What Happened
Jennifer Kayden Lee, EVP and Head of North America at Rhythm Pharmaceuticals (RYTM), received derivative equity awards on February 11, 2026: 21,650 restricted stock units (RSUs) and 32,500 stock options. Both awards were reported with a $0 acquisition price (typical for grants/awards), so no cash changed hands at grant. These are compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (filed within the normal two-business-day window).
• Awards: 21,650 RSUs (footnote F1) and 32,500 stock options (footnote F3). Combined total = 54,150 derivative units. Reported price: $0.
• RSU vesting (F2): 25% of the RSUs vest on each of Feb 1, 2027, Feb 1, 2028, Feb 1, 2029 and Feb 1, 2030. RSUs have no expiration date per the footnote.
• Option vesting (F3): Options granted Feb 11, 2026 vest in 16 substantially equal installments upon completion of each three full months of successive service following the grant date (i.e., quarterly over ~4 years).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Filing timeliness: No late filing indicated.

Context

• RSUs are a contingent right to receive one share upon vesting; they are not immediate purchases. Stock options give the holder the right to buy shares according to the option terms once vested. Neither award represents an immediate sale or buy in the open market.
• These awards are routine forms of executive compensation and do not by themselves indicate insider buying or selling sentiment.